16-30 of 31
Evolving Therapy for Managing Pediatric Narcolepsy: Once-Nightly Sodium Oxybate
MinuteCE®Evolving Therapy for Managing Pediatric Narcolepsy: Once-Nightly Sodium Oxybate
Anne M. Morse, DO
Narcolepsy’s Burden of Illness: Its Impact on the Child and Family
MinuteCE®Narcolepsy’s Burden of Illness: Its Impact on the Child and Family
Anne M. Morse, DO
Evolving Therapy for Managing Pediatric Narcolepsy: Wake-Promoting Pitolisant
MinuteCE®Evolving Therapy for Managing Pediatric Narcolepsy: Wake-Promoting Pitolisant
Funke Afolabi-Brown, MD
Current Pharmacologic Approaches to Managing Pediatric Narcolepsy
MinuteCE®Current Pharmacologic Approaches to Managing Pediatric Narcolepsy
Kiran Maski, MD, MPH
Key Differences Among the Clinical Manifestations of Narcolepsy Symptoms in Children Versus Adults
MinuteCE®Key Differences Among the Clinical Manifestations of Narcolepsy Symptoms in Children Versus Adults
Funke Afolabi-Brown, MD
Can We Talk? Optimizing Patient and Parent/Caregiver Buy-in to the Management of Pediatric Narcolepsy
MinuteCE®Can We Talk? Optimizing Patient and Parent/Caregiver Buy-in to the Management of Pediatric Narcolepsy
Anne M. Morse, DO
- advertisement
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
CME/CEDuchenne Muscular Dystrophy: Differentiating Advances in Treatment
Omer Abdul Hamid, MD
Nancy Kuntz, MD
Migvis Monduy, MD
CASR and ADH1: Integrating Biology and Genetic Screening
MinuteCE®CASR and ADH1: Integrating Biology and Genetic Screening
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Emerging Therapeutics in ADH1: Progress in Precision Medicine
MinuteCE®Emerging Therapeutics in ADH1: Progress in Precision Medicine
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
MinuteCE®Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
Therapeutic Options for ADH1 and Hypoparathyroidism
MinuteCE®Therapeutic Options for ADH1 and Hypoparathyroidism
Michael A. Levine, MD, FAAP, MACE, FACP
B. Michelle Schweiger, DO, MPH
- advertisement
Titrating and Dosing Device Therapy for DRE: Best Practices for Optimizing Patient Outcomes
CME/CETitrating and Dosing Device Therapy for DRE: Best Practices for Optimizing Patient Outcomes
Danielle Becker, MD, MS, FAES
Ahmed Abdelmoity, MD
Deborah Holder, MD
John Stern, MD
Evolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
CME/CEEvolving Perspectives in PIK3CA-related Overgrowth Spectrum Diagnosis & Treatment
William Mencia, MD, FACEHP
Julie Blatt, MD
Taizo Nakano, MD
Combining Biologics in a Young Patient with Atopic Dermatitis
CME/CECombining Biologics in a Young Patient with Atopic Dermatitis
Peter A. Lio, MD
Mark Boguniewicz, MD
Eric Simpson, MD, MCR
